HAE Management and Treatment

CE / CME

Expert Guidance on HAE Management and the Evolving Landscape of Prophylaxis

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 25, 2025

Expiration: March 24, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this module, Marc Riedl, MD, MS, discusses the evolving management landscape for hereditary angioedema (HAE), including expert strategies to provide guideline-concordant care when using on-demand therapy and short- or long-term prophylaxis, as well as why patient-centered care is critical to improving health outcomes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with HAE do you provide care for in a typical month?

A 28-year-old woman presents to your clinic with a history of recurrent, nonpitting swelling involving her face, extremities, and abdomen. Each episode lasts 2 to 3 days, is not associated with urticaria, and does not respond to antihistamines. Which of the patient's symptoms are most suggestive of HAE?

Which of the following statements most accurately reflects the findings from the phase III OASIS-HAE trial evaluating donidalorsen for prophylactic treatment in patients with HAE?

A 17-year-old patient with HAE is starting long-term prophylaxis before moving to college. He prefers a regimen with infrequent dosing, high efficacy, and low risk of adverse events (AEs). Which of the following would  you recommend?